Elevara Medicines

Elevara Medicines Limited is a biotechnology company dedicated to advancing treatment options for rheumatoid arthritis. Founded in 2025, it is headquartered in London, UK.Elevara Medicines focuses on the development of innovative therapies for rheumatoid arthritis (RA) and chronic inflammatory diseases, with a core product being ELV001, a once-daily small molecule designed to target the proliferation and inflammatory signaling of fibroblast-like synoviocytes (FLS). This product aims to address the unmet needs of patients who have not achieved adequate disease remission through existing immune-targeted treatments, particularly those with partial response to TNF inhibitors. The company is actively conducting the START-SYNERGY Trial, a Phase 2b clinical study evaluating ELV001 as an add-on therapy for patients experiencing inadequate responses to standard treatments like methotrexate and TNF inhibitors. The revenue model will involve partnerships with healthcare providers and clinics for the distribution of ELV001 and future products within the RA treatment landscape. Transactions are likely to be structured as B2B agreements, engaging directly with hospitals and specialty pharmacies to facilitate access to their therapies, aiming to streamline treatment processes for patients and enhance compliance. With its ongoing clinical studies, Elevara aims to establish a strong market presence and enhance its product offerings in the rheumatoid arthritis and chronic inflammatory disease sectors.

1. Series A

   Oct 2, 2025

   Amount

   $70M

   Investors

   Locked